Suppr超能文献

GABARAPL1 的缺失赋予肝癌干细胞样细胞对铁死亡的抗性。

Loss of GABARAPL1 confers ferroptosis resistance to cancer stem-like cells in hepatocellular carcinoma.

机构信息

Department of Gastroenterology, Minhang Hospital, Fudan University, Shanghai, China.

Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, China.

出版信息

Mol Oncol. 2022 Oct;16(20):3703-3719. doi: 10.1002/1878-0261.13305. Epub 2022 Sep 5.

Abstract

Cancer stem-like cells (CSLC) are considered a major contributor to the development and progression of hepatocellular carcinoma (HCC). Previous studies indicated that CSLC are characterized by resistance to ferroptosis, a type of lipid peroxidation-dependent cell death. Here, we identified a set of ferroptosis-related stemness genes (FRSG) and found that these genes may be involved in immune infiltration in HCC. A four-FRSG (CDKN2A, GABARAPL1, HRAS, RPL8) risk model with prognostic prediction was constructed by a Cox analysis in HCC. Among these four genes, GABARAPL1 was downregulated in HCC tumor-repopulating cells (TRC; a type of CSLC). Its downregulation decreased the sensitivity of HCC TRC to erastin- or sorafenib-triggered ferroptosis. Together, we uncovered a molecular mechanism via which CSLC could achieve tolerance to ferroptosis. Further studies may provide potential therapeutic strategies targeting CSLC in HCC.

摘要

癌症干细胞样细胞(CSLC)被认为是肝癌(HCC)发生和进展的主要原因。先前的研究表明,CSLC 的特征是对铁死亡的抵抗力,铁死亡是一种依赖脂质过氧化的细胞死亡。在这里,我们确定了一组与铁死亡相关的干性基因(FRSG),并发现这些基因可能参与 HCC 的免疫浸润。通过 HCC 的 Cox 分析构建了一个包含四个 FRSG(CDKN2A、GABARAPL1、HRAS、RPL8)的风险模型,用于预测预后。在这四个基因中,GABARAPL1 在 HCC 肿瘤再生细胞(TRC;一种 CSLC)中下调。其下调降低了 HCC TRC 对 erastin 或 sorafenib 触发的铁死亡的敏感性。总之,我们揭示了 CSLC 实现对铁死亡耐受的分子机制。进一步的研究可能为 HCC 中针对 CSLC 的潜在治疗策略提供依据。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验